reason report
hiv survey rapid adopt biktarvi
challeng outlook gsk
bottom line hiv treatment market becom
categori domin gilead mp gsk mp
categori central valuat gilead
import valuat gsk gilead newli introduc
biktarvi gsk advanc dolutegravir base combin
potenti disrupt current treatment pattern
trend categori assess impact introduct
recent complet medacorp survey us hiv treatment
specialist survey found impress posit sentiment
fixed-dos combin seem like put sustain pressur
gsk lead integras inhibitor tivicay well cannib
gilead combin compon product survey respond
estim penetr integras inhibitor estim
increas patient gsk/viiv
dolutegravir-bas regimen tivicay/triumeq expect declin
integras inhibitor regimen two year
biktarvi share estim reach integras inhibitor
market increas gild share respond see place
viiv two drug regimen patient stabl integras
inhibitor regimen survey also suggest tivicay novemb
dolutegravir-bas regimen medacorp specialist
either plan alreadi chang prescrib habit
survey respond suggest gilead commerci execut
support biktarvi launch effect beyond
immedi term disrupt event categori includ
introduct gener version gilead viread year gener
version truvada atripla complera descovi late base
survey updat market compani model
hiv product incorpor faster deeper share gain biktarvi
greater eros tivicay well cannib gilead
exist product longer term includ rapid gener eros
gilead legaci combin product gener entri littl
secondari effect avail adopt remain
implic gsk
eu specialist confirm like rapid adopt biktarvi
europ limit role doublet spoke eu
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
hiv kol get eu perspect survey result accord
specialist patient dolutegravir taf-bas
regimen descovi emtricitabin tenofovir alafenamid view
introduct biktarvi offer integras inhibitor equival viiv
dolutegravir superior taf-bas backbon envis
immedi switch biktarvi expect steadi migrat
exist medic patient return clinic routin care
refil despit potenti econom argument support use
gsk two-drug regimen expect patient get
two-drug combin due lack physician sensit
econom argument compar efficaci safeti gsk two-
drug regimen provid therapeut coverag hiv patient risk
develop hepat particularli import given rise
hepat certain part world
gild biktarvi major headwind viiv
increment cautiou gsk near-term cut tivicay/triumeq
estim gsk valuat two-drug pipelin strategi key
viiv futur growth prospect lower estim tivicay/
triumeq estim
partial off-set sale contribut viiv
two-drug pipelin product dolutegravir lamivudin cabotegravir
rilpivirin forecast launch respect
total sale line factset consensu
sale previous
consensu net chang survey result gsk
pt heavili reliant success
viiv two-drug strategi return growth compani
leerink gilead hiv forecast increas account faster biktarvi higher
share offset eros product base result proprietari
survey specialist interview updat revenu forecast gilead hiv
medicin specif increas biktarvi forecast reduc descovi
forecast sinc much biktarvi rapid earli adopt seem like come descovi
lesser extent truvada use gsk tivicay medium term also
assum biktarvi captur share notabl legaci combin
atripla complera taf-bas odefsey like continu share gain expens
complera genvoya like declin somewhat moder given reason satisfact
treatment among physician patient longer term still forecast biktarvi
becom biggest product ever hiv treatment categori revenu
grow almost peak sale biktarvi forecast assum
product maintain current net price captur market share
rate genvoya gilead recent success hiv str launch
taken care account eros mani product lose exclus gilead hiv
portfolio truvada atripla vemlidi descovi expect product
rapidli generic materi affect adopt use biktarvi genvoya
least us market overal hiv revenu forecast gilead slightli consensu
increas period forecast
suggest total growth hiv busi
forecast declin hiv revenu due mani loss exclus
loe event year total hiv revenu forecast consensu
higher expect sale peak
make chang total revenu forecast gilead larg line consensu
higher consensu
continu forecast revenu gilead round-trip peak
back updat forecast consist
promis outlook biktarvi also signific cannib gilead
product well import gener launch event
given forecast rel flat oper margin later year
ep estim larg unchang increas
later year adjust ep estim line recent consensu
lower recent consensu later year given
expect eros franchis late due patent expiri
appli termin cash flow growth rate beyond approach well
sum-of-the-part compar price sale price earn multipl approach
suggest fair valu gilead stock rang averag approach
adjust price target
evolut integras inhibitor market mean gsk beyond
confer call monday februari survey highlight implic gsk
survey us infecti diseas specialist assess current market potenti futur use hiv drug
regimen focu integras inhibitor class launch gild biktarvi
major hiv popul rel stabl year-to-year patient drug regimen
expect regimen
integras inhibitor alreadi lead class across sever hiv patient segment growth expect continu
 respond estim hiv patient prescrib integras inhibitor physician anticip
patient integras inhibitor
 patient consid either new treatment chang drug regimen receiv integras
inhibitor part hiv regimen
 patient progress switch new hiv drug regimen treatment receiv integras inhibitor part
hiv regimen
 dolutegravir-bas drug regimen use hiv patient treat integras inhibitor highest util
among academ govern center
 physician prefer conveni singl pill regimen highlight side effect area improv
medacorp specialist plan chang dolutegravir tivicay prescrib habit result
label updat includ hepatotox risk loss virolog respons due concomit use drug
respond predict rapid uptak gild biktarvi bictegravir/emtricitabine/tenofovir alafenamid
treatment nave/st progress to/switch new regimen respect
 physician anticip first line patient migrat biktarvi therapi util dolutegravir base therapi
triumeq tivicay dolutegravir two-drug regimen declin rapidli first line
physician see modest uptak gsk dual-drug combin dolutegravir rilpivirin dolutegravir lamivudin
expect uptak first line therapi later line
lower estim tivicay/triumeq estim
includ estim impact gsk two-drug pipelin regimen juluca
forecast separ tivicay/triumeq sale viiv two-drug regimen dolutegravir
lamivudin cabotegravir rilpivirin estim launch respect
balanc survey suggest signific challeng viiv neg gsk
sale consensu
net chang survey result gsk pt near-
term ep growth prospect challeng viiv critic import gsk cash flow dividend
cover warrant cautiou stanc stock despit appear reason valuat
increas biktarvi forecast reduc descovi forecast base assumpt
switch tivicay descovi
genvoya like declin somewhat moder given reason satisfact treatment among
physician patient
forecast biktarvi becom biggest product ever hiv treatment categori revenu
grow almost peak sale
account eros mani product lose exclus gilead hiv portfolio
expect rapid generic affect brand spillov impact biktarvi
total hiv revenu forecast unchang higher later year
forecast consensu higher
geograph distribut survey particip
va
hiv patient aggreg
mean patient median
physician anticip increas
patient volum next two year
major physician
academ medic center privat
practic commun
averag pt
median pt
respond practic reflect age hiv patient popul
half medicar medicaid
physician survey
practic year
half patient
half patient commun practic year
medic centercommun hospitalpriv practiceva govern facilityhiv/hmo yr despit effect therapi
hiv hiv-rel diseas continu signific societ burden
factsheet aid epidem
hiv
live
individu
peopl live hiv
access
note dhss- depart human servic
viiv establish
partnership
gsk viiv portfolio
hiv treatment gener
repres gsk total
grow high mid-singl
digit
factset evaluatepharma leerink partner research
viiv total gsk sale
ingelheimglaxosmithklinemerck cobristol-my squibbgilead sciencesjohnson johnsonoth hiv largest part gilead growth outlook valu
estimate valu gilead asset
creat modern hiv
atripla
launch fdc
biktarvi hiv gener
gild revenu
grow high singl
version gild drug
come
market challeng
factset evaluatepharma leerink partner research
patient expect regimen
patient drug therapi percentag treatment nave new start stabl patient chang
hiv drug regimen progress to/switch new therapi new drug ad least one agent hiv
drug regimen replac fail avail regimen
base survey
switch opportun
new therapi
total patient
similar dynam
note treatment nave new treatment start calendar year
stabl chang hiv drug regimen calendar year
progress new therapi ad replac current treatment
treatment failur end treatment due lack respons new start
new start stabl chang hivdrug regimen progress to/switchedto new therapytreat failur integras inhibitor use alreadi high still expect grow
percentag total treatment nave/st patient patient progress to/switch receiv
follow class agent part drug regimen expect
note treatment nave new treatment start calendar year
stabl chang hiv drug regimen calendar year
progress new therapi ad replac current treatment
treatment failur end treatment due lack respons new start
physician awar high regard gild biktarvi
familiar clinic data integras inhibitor bictegravir gilead part fixed-dos
combin emtricitabin ftc /tenofovir alafenamid taf clinic data gsk/viiv two drug regimen
clinic data clinic heard familiar biktarvi dataclin data clinic heard familiar dtg rpv dataclin data clinic heard familiar dtg tivicay safeti updat risk give signific potenti
market counter-detail gsk new combin
novemb fda updat tivicay dolutegravir label includ risk hepatotox risk advers
reaction loss virolog respons due concomit use drug pleas indic view label
updat whether chang tivicay prescript habit
survey physician
plan chang dolutegravir
prescrib habit result
awar butthi changedmi prescript habitsy awar andthi chang myprescript habitsno awarebut like tochang myprescript habitsno awarebut unlik tochang myprescript habit dolutegravir-bas regimen use hiv patient across
variou center highest util academ va/govt center
hiv patient treat integras inhibitor percentag receiv follow
base physician survey hiv patient receiv dolutegravir-bas
tivicay triumeq higher use among academ center va/govt
gov tfacilityacademiccentercommunityhospitalprivatepracticeva gov tfacilitynave/stableprogress/switchotherstribildisentressgenvoyativicaytriumeq physician prefer conveni single-pil regimen
side effect offer opportun improv
primari reason patient discontinu pleas rank agent categori
per agent primari reason reason/not factor
base respons treatment continu survey physician prefer
conveni singl pill regimen genvoya triumeq stribild identifi side effect
import reason discontinu singl pill regimen
effectsconveniencetolerabilityinsuffici viralsuppressionisentress nrtitivicay nrtitriumeqstribildgenvoyaworst isentress nrtibest tivicay nrtiworst triumeqbest isentress nrtiworst isentress nrtibest genvoyaworst triumeq/stribildbest isentress nrti physician expect rapid uptak gild biktarvi naive/st patient
impact gsk tivicay gild genvoya descovi
see integras inhibitor use evolv nave/st patient
physician anticip util biktarvi
nave/st patient
percentag point drop gsk share
integras inhibitor market among
nave/st patient
inhibitor market share interestingli respond expect biktarvi even better patient
progress switch new therapi
see integras inhibitor use evolv patient progress to/switch
physician anticip slightli higher use biktarvi
progressing/switch patient
physician expect gsk share
integras inhibitor market
end
triumeq inhibitor market physician modest uptak gsk dual-combin
treat patient percentag estim receiv dolutegravir-bas two-drug regimen
next month next month next month
physician expect similar modest uptak dolutegravir-bas two drug regimen
dolutegravir rilpivirin dolutegravir lamivudin nave/st switch
patient next month
centercommunityhospitalpriv practiceva orgovernmentfacilityoth centercommunityhospitalprivatepracticeva orgovernmentfacilityoth specifi aggreg integras inhibitor primarili use first second line therapi
third later patient still get dolutegravir-bas regimen
think patient line therapi current prefer regimen treat hiv patient
line therapi
integras inhibitor use patient nearli
fdc strongli prefer
integras inhibitor use
first second-lin therapi
patient third later
line therapi patient
linethird later linethird later linegskgildoth gsk dual-drug combin like better among
first-line/st hiv patient biktarvi major headwind
dolutegravir two-drug regimen approv percentag patient would prescrib agent
gsk emerg two-drug combin could captur share line patient
physician expect lower use later line
linesecond linethird later physician expect gild biktarvi domin first line hiv therapi
look forward two year envis treatment choic line therapi
physician expect first line patient migrat biktarvi expect
use dolutegravir base regimen triumeq tivicay dolutegravir two-drug regimen
fall
linethird later regimenoth market integrasebas regimen tivicay dolutegravir anynrti-bas backbonetriumeqdtg -dual drug linethird later share integras linethird later share integras hiv commerci support view substanti effect
viiv ensur effect execut biktarvi launch
effect compani get patient request new therapi
mani time repres follow sale forc visit past six month
extrem effect effect rep visit last month model chang
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
figur except per share data
old old old old profit forecast sg forecast sale forecast sg forecast forecast sale gross profit margin forecast cog forecast
number respond
respons repres averag aggreg respons unless otherwis note
screener best describ specialti
screener mani hiv patient practic mani expect practic
set see major hiv patient
va govern facil
follow best describ set institut see major hiv patient
mani year practic
less year
year
percentag hiv patient fall within follow age group
percentag hiv patient medic cover follow method
white fund va ryan white va care
hiv patient drug therapi percentag treatment nave new start stabl patient chang
hiv drug regimen progress to/switch new therapi new drug ad least one agent hiv drug
regimen replac fail avail regimen pleas estim percentag patient like group
stabl chang hiv drug regimen
progress to/switch new therapi
percentag total treatment nave stabl patient receiv follow class agent part
drug regimen expect
third agent dual drug fusion juluca nrti spare
percentag patient progress to/switch new therapi receiv follow class
agent part drug regimen expect
note total exceed due combin therapi
third agent dual drug fusion inhibitor ibilizumab
juluca spare maraviroc pharmacokinet booster
familiar clinic data integras inhibitor bictegravir gilead part fixed-dos
combin emtricitabin ftc /tenofovir alafenamid taf clinic data
familiar data clinic investig
heard familiar data
click phase clinic data
treatment nave new start stabl patient treat integras inhibitor percentag receiv
follow expect chang
tivicay dolutegravir nrti-bas backbon
isentress raltegravir nrti-bas backbon
patient progress to/switch integras inhibitor base regimen percentag receiv
follow expect chang
tivicay dolutegravir nrti-bas backbon
isentress raltegravir nrti-bas backbon
tivicay nrti-bas backbon
isentress nrti-bas backbon
case basi complera dolutegravir lamivudin
maxim
switch
primari reason patient discontinu pleas rank agent categori
per agent
novemb fda updat tivicay dolutegravir label includ risk hepatotox risk advers
reaction loss virolog respons due concomit use drug pleas indic view label updat
whether chang tivicay prescript habit
ye awar chang prescript habit
ye awar chang prescript habit
awar like chang prescript habit
awar unlik chang prescript habit
familiar clinic data gsk/viiv two drug regimen dolutegravir rilpivirin and/or dolutegravir
heard
familiar
data
familiar
data clinic
click dolutegravir two-drug regimen clinic data
treat patient percentag estim receiv dolutegravir-bas two-drug regimen next
month next month next month
treatment nave stabl patient
progress to/switch patient
think patient line therapi current prefer regimen treat hiv patient
line therapi
tivicay dolutegravir nrti-bas backbon
look forward two year envis treatment choic line therapi
tivicay dolutegravir nrti-bas backbon
dolutegravir two-drug regimen approv percent patient would prescrib agent
third later line
effect compani get patient request new therapi
effect
mani time repres follow sale forc visit past six month
major market messag
appendix summari respons
question major market messag
consid drug regimen tivicay core agent
dolutegravir prescrib drug
tivicay base
dolutegravir prescrib insti
safeti tivicay
eas use/suppress
dolutegravir core hiv treatment
juluca smallest complet regimen
triumeq us
dolutegravir core treatment
efficaci tivicay mani differ popul
get baselin hla lack booster w/dtg
efficaci dolutegravir base regimen data drug regimen
tivicay use ist
triumeq good juluca worth tri
look data
dolutegravir backbon potent easili toler hiv treatment conveni singl pill
triumeq juluca
bictegravir booster
descovi base
eas use/suppress
ftc-taf core hiv treatment
genvoya robust well toler complet insti/taf/ftc regimen
singl tablet regimen prescrib
prep genvoya good
watch new medic approv
proven conveni one pill
look data
rate gilead stock market perform price target downgrad
stock sept chang hepat market forecast compani
erod sharpli sooner anticip specif see patient
volum declin steadili initi peak market revenu yield per patient
continu trend neg base decreas treatment durat increas discount
manufactur compet govern commerci contract posit forecast hcv
sale declin subsequ year due competit market
dynam outlook compani hiv busi remain posit suffici
off-set unusu dynam hcv busi rel modest contribut
product offer littl mitig effect boom bust hcv forecast
total hcv revenu fall short current consensu like drive
signific neg margin trend given hcv extrem strong profit hope
gilead intern develop pipelin busi develop invest could off-set
risk opportun appear arriv late littl valu high
price gilead manag miss sever attract transact opportun
paid high premium enter oncolog market cellular therapi without declar
competit advantag gilead valuat current all-tim low like recov
rel peer earn declin potenti continu neg revis
substanti termin uncertainti make hard us recommend stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough
consensu forward earn multipl slow-growth medic product stock celg
sni appli ep estim gilead give price
altern appli slow-grow large-cap medic product us pharma spec pharma
eu pharma revenu multipl revenu estim deriv impli valu
impli one year price target use sum part valuat exist
franchis get price consist primarili price compani hiv
franchis hcv product lastli dcf use forecast free cash flow
appli growth rate termin cash flow forecast discount
valu back present wacc give present valu averag
four approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip
pipelin asset bictegravir hiv filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv hcv
product success develop underappreci element compani portfolio
momelotinib selonsertib entospletinib stronger-than-expect convers current
hiv patient gilead next gener taf-bas hiv treatment regimen
rate gsk market perform exist investor gsk offer busi divers
project revenu deriv long-dur asset vaccin
biolog consum product top-tier dividend yield option
realist break-up busi howev believ factor rel evenli
balanc risk intensifi competit compani respiratori devic
 hiv franchis account global sale even greater proport ep
near-to medium-term dividend pay-out ratio strangl capit alloc option
forecast ep includ impact nvs-gsk swap compound-annual-growth-rate
gsk trade line compani coverag univers azn nv nvo
sni improv visibl base year earn dcf valuat
gsk
forecast ep compound-annual-growth-rate reflect gener competit competit
pressur hiv partial off-set new product growth base pro forma dcf includ
impact nvs-gsk swap forecast sale profit believ gsk
could trade next month
risk gsk includ launch advair gener slow breo anoro growth
greater anticip impact competit hiv busi follow fda guidanc
medacorp regulatori specialist place high probabl anda approv respiratori
devic
figur except per share data
urolog cvmu
stem cell gene therapi ada-scid
corpor unalloc turnov
figur except per share data
corpor unalloc turnov
sale
sale
sale
sale
sale
dispos interest associ
sale
net incom minor int
sale
tax benefit synergies/financ
net incom minor int
sale
adr ep us
dilut share outstand
basic share outstand
 core ep excl impair intang asset legal charg asset gain loss
figur except per share data
corpor unalloc turnov
sale
sale
sale
sale
sale
dispos interest associ
sale
net incom minor int
sale
tax benefit synergies/financ
net incom minor int
sale
adr ep us
dilut share outstand
basic share outstand
 core ep excl impair intang asset legal charg asset gain loss
million
darunavir/c/f-taf royalti
darunavir/c/f-taf royalti
leerink partner research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
leerink revenu estim gilead
comp ex growth larg cap revenu multipl celg
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
leerink partner research compani file factset
